


Ovarian Cancer Screening

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Note: Screening is only intended for asymptomatic individuals. Patient must be a candidate for and is willing to undergo curative treatment. Ovarian cancer screening may continue as long as a woman has a 10-year life expectancy and no co-morbidities that would limit the diagnostic evaluation or treatment of any identified problem. There is currently no ovarian cancer screening test that has been shown to improve outcomes for women at any level of ovarian cancer risk.



¹ Signs and symptoms include:

- Pelvic or abdominal pain
- Increased abdominal size/bloating
- Difficulty eating/feeling full
- Fatigue
- Changes in bowel/bladder habits

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Goff, B. A., Mandel, L. S., Drescher, C. W., Urban, N., Gough, S., Schurman, K. M., . . . Andersen, M. R. (2007). Development of an ovarian cancer symptom index: Possibilities for earlier detection. *Cancer, 109*(2), 221-227. <https://doi.org/10.1002/cncr.22371>
- Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., . . . Offit, K. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *The New England Journal of Medicine, 346*(21), 1609-1615. <https://doi.org/10.1056/NEJMoa020119>
- Lindor, N. M., Petersen, G. M., Hadley, D. W., Kinney, A. Y., Miesfeldt, S., Lu, K. H., . . . Press, N. (2006). Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: A systematic review. *Journal of the American Medical Association, 296*(12), 1507-1517. <https://doi.org/10.1001/jama.296.12.1507>
- National Comprehensive Cancer Network. (2022). *Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic*. (NCCN Guideline Version 2.2022). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
- Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., . . . Weber, B. L. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *The New England Journal of Medicine, 346*(21), 1616-1622. <https://doi.org/10.1056/NEJMoa012158>
- Schorge, J. O., Modesitt, S. C., Coleman, R. L., Cohn, D. E., Kauff, N. D., Duska, L. R., . . . Herzog, T. J. (2010). SGO white paper on ovarian cancer: Etiology, screening and surveillance. *Gynecologic Oncology, 119*(1), 7-17. <https://doi.org/10.1016/j.ygyno.2010.06.003>

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.*

DEVELOPMENT CREDITS

This screening algorithm is based on majority expert opinion of the Ovarian Cancer Screening workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads

Therese Bevers, MD (Cancer Prevention)
Ana Nelson, DNP, APRN, FNP-BC (Cancer Prevention)
Shannon Westin, MD (Gynecologic Oncology & Reproductive Medicine)

Workgroup Members

Heather Alexander, PgDip, BA (Community Alliances)
Powel Brown, MD, PhD (Cancer Prevention)
Robin Coyne, MSN, RN, FNP (Cancer Prevention)
Joyce Dains, DrPH, JD, RN, FNP-BC, FNAP, FAANP (Nursing)
Molly Daniels, MS, CGC (Cancer Genetics)
Wendy Garcia, BS[♦]
Ernest Hawk, MD (Cancer Prevention)
Karen Lu, MD (Gynecologic Oncology & Reproductive Medicine)
Denise Nebgen, MD, PhD (Gynecologic Oncology & Reproductive Medicine)
Lonzetta Newman, MD (Cancer Prevention)
Lois Ramondetta, MD (Gynecologic Oncology & Reproductive Medicine)

[♦] Clinical Effectiveness Development Team